drugset / Trial / NCT00622674
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving bortezomib together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with cetuximab in treating patients with advanced solid tumors.
Timeline
- Start
- 2005-11
- Primary completion
- 2009-08
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.7 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.8 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.9 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 2 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |